Australiahealth

Argenica Therapeutics (ASX:AGN) has formed a Clinical Advisory Committee to lead its Phase 2b trial for the neuroprotective candidate, ARG-007.

Nexalis Therapeutics (ASX:NX1) announced a clinical milestone following the final dosing of its Phase 1 study for IRX-616a.

Neurizon Therapeutics (ASX:NUZ) secures ethics approval for a Phase 1 study of its NUZ-001 oral liquid formulation.

Firebrick Pharma (ASX:FRE) has achieved a regulatory milestone in North America with the Canadian Intellectual Property Office.

Nexsen (ASX:NXN) has achieved a milestone in its international expansion, announcing a binding term sheet with GHK Hospital.

Cancer diagnostics firm Pacific Edge (ASX:PEB) has capitalised on investor appetite, announcing an upsized NZ$25.4 million equity placement.

Healius (ASX:HLS) narrowed its EBITDA guidance to $259M–$264M and launched a strategic asset review for FY26.

Biome Australia (ASX:BIO) executed a two-year extension to its exclusive supply agreement with Probiotical.

Bioxyne (ASX:BXN) announced a major $50 million exclusive supply agreement with German pharmaceutical giant ADREXpharma.

EMVision Medical Devices (ASX:EMV) announced an expansion of its pivotal FDA De Novo trial.